Fig. 4.
Systemic evaluation of cisplatin@DEXxcl1 for antitumor immunity in subcutaneous prostate cancer mice. Subcutaneous tumor-bearing C57BL/6 mice were treated with cisplatin (30 mg/kg, i.v injection), DEXxcl1 or cisplatin@DEXxcl1 (80ug/mouse/week for three weeks, s.c injection), NC (normal control) refers to PBS treated group. A, B Tumor size and weight (g) of nude mice in different treatment groups; C Measurement of tumor volume at different time-points after inoculation. Significant differences were obtained between cisplatin@DEXxcl1 and other groups. D Survival rate of treated subcutaneous tumor-bearing mice (n = 4, *P < 0.05, **P < 0.01, ***P < 0.001)